Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
A Multi-center, Open-label, Single-arm Phase I Clinical Study to Evaluate the Safety and Tolerability of Inaticabtagene Autoleucel Injection in Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
Sponsor: Juventas Cell Therapy Ltd.
Listed as NCT06826430, this PHASE1 trial focuses on Autoimmune Thrombocytopenia and remains actively recruiting participants. Sponsored by Juventas Cell Therapy Ltd., it has been updated 2 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
2 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Juventas Cell Therapy Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .